Search Login Register

Medullary Carcinoma Summary

Description: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)

Also Known As: Carcinoma, Medullary; Carcinomas, Medullary; Medullary Carcinomas

Networked: 882 relevant articles (12 outcomes, 68 trials/studies) for this Disease

Key Drugs and Agents for Medullary Carcinoma

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. Calcitonin (Calcitonin, Eel) : 6 outcomes 21 studies in 271 results : FDA 1 Generic
  2. Thyroglobulin : 1 outcome 4 studies in 34 results : FDA 2
  3. Carcinoembryonic Antigen : 1 outcome 4 studies in 30 results : IBA
  4. Antibodies : 1 outcome 3 studies in 13 results : IBA
  5. Pentagastrin (Peptavlon) : 1 outcome 2 studies in 31 results : FDA 1
  6. 3-Iodobenzylguanidine (Iobenguane) : 1 outcome 1 study in 13 results : IBA
  7. Cisplatin (Platino) : 1 outcome in 5 results : FDA 6 Generic
  8. gemcitabine : 1 outcome in 3 results : FDA 7
  9. calretinin : 1 outcome in 2 results : IBA
  10. anti-thyroglobulin : 1 outcome in 2 results : IBA
Show All >>

Diseases Related to Medullary Carcinoma

  1. Neoplasms (Cancer)
  2. Carcinoma (Carcinomatosis)
  3. Carcinoid Tumor (Carcinoid)
  4. Neoplasm Metastasis (Metastasis)
  5. Paraganglioma (Paragangliomas)
Show All >>

Key Therapies for Medullary Carcinoma

Efficacy Chart >>
  1. Drug Therapy (Chemotherapy) : 1 outcome in 20 results
  2. Thyroidectomy : 2 studies in 67 results
  3. Jejunoileal Bypass : 1 study in 1 result
  4. Radiotherapy : 12 results
  5. Lymph Node Excision (Lymph Node Dissection) : 10 results
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.